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CRISPR/Cas9 induces DNA double-strand breaks
that are repaired by cell-autonomous repair path-
ways, namely, non-homologous end-joining (NHEJ),
or homology-directed repair (HDR). While HDR is
absent in G1, NHEJ is active throughout the cell cycle
and, thus, is largely favored over HDR. We devised a
strategy to increase HDR by directly synchronizing
the expression of Cas9 with cell-cycle progression.
Fusion of Cas9 to the N-terminal region of human
Geminin converted this gene-editing protein into a
substrate for the E3 ubiquitin ligase complex APC/
Cdh1, resulting in a cell-cycle-tailored expression
with low levels in G1 but high expression in
S/G2/M. Importantly, Cas9-hGem(1/110) increased
the rate of HDR by up to 87% compared to wild-
type Cas9. Future developments may enable high-
resolution expression of genome engineering pro-
teins, which might increase HDR rates further, and
may contribute to a better understanding of DNA
repair pathways due to spatiotemporal control of
DNA damage induction.
INTRODUCTION
The ability to modify the genetic information of an organism en-
ables one to study the function of its genes, e.g., during normal
development. Moreover, genome editing holds the promise to
model and reverse disease-causing variants on the cellular and
organismal level. However, until recently, easy-to-use, flexible,
and efficient genome-editing tools were missing. The discovery
of the RNA-guided endonuclease Cas9 from the type II CRISPR
(clustered regularly interspaced palindromic repeats) system
revolutionized the field of genome engineering. Initially, CRISPRs
had been discovered in bacteria and archaea (Ishino et al., 1987;
Mojica et al., 2000) and were later shown to be derived from
plasmid and viral origins (Bolotin et al., 2005; Mojica et al.,
2005; Pourcel et al., 2005). The CRISPR-Cas system was finallyCell Rcharacterized as an adaptive defense system targeting foreign
nucleic acids (Barrangou et al., 2007; Brouns et al., 2008; Mar-
raffini and Sontheimer, 2008). The three known CRISPR-Cas
systems use different mechanisms to achieve nucleic acid
recognition and cleavage (Makarova et al., 2011a, 2011b). While
type I and type III systems use large multiprotein complexes, the
type II system requires only a single protein, Cas9, to achieve
RNA-guided DNA recognition and cleavage (Gasiunas et al.,
2012; Hale et al., 2009; Haurwitz et al., 2010; Jinek et al.,
2012). Cas9 is a large multifunctional protein with two nuclease
domains, HNH and RuvC-like, acting together to introduce
DNA double-strand breaks (DSBs) into invading plasmids and
phages (Bolotin et al., 2005; Garneau et al., 2010; Haft et al.,
2005; Makarova et al., 2006). The S. pyogenes CRISPR-Cas9
protein depends on a tracrRNA (trans-activating crRNA [CRISPR
RNA]) and requires the formation of a tracrRNA:crRNA duplex to
direct DNA cleavage (Deltcheva et al., 2011; Jinek et al., 2012). In
2013, the CRISPR-Cas9 system was put into the spotlight of
genome engineering: three studies used humanized versions of
S. pyogenes and S. thermophiles Cas9, together with either
custom-designed single-guide RNAs (sgRNAs) or tracrRNA co-
expressed with custom-designed crRNAs, to edit the genome
of human and murine cells (Cong et al., 2013; Jinek et al.,
2013; Mali et al., 2013b). Since then, Cas9-mediated genome
editing has been applied to various mammalian cell systems
and diverse model organisms (Doudna and Charpentier, 2014;
Hsu et al., 2014; Mali et al., 2013a; Sander and Joung, 2014).
Once recruited to its target sequence in eukaryotes, Cas9 in-
duces a DNA DSB, which is repaired either by the non-homolo-
gous end-joining pathway (NHEJ) or by homology-directed repair
(HDR). While the NHEJ pathway is important for the creation of
loss-of-function alleles due to the generation of variable insertions
and deletions (indels), the HDR pathway enables precise repair
or site-specific integration of exogenous DNA sequences into
the genome. The ability of Cas9 to introduce DSBs at defined,
customizable positions has made it possible to reproduce tu-
mor-associated alterations in cellulo and in living animals (Choi
andMeyerson, 2014; Maddalo et al., 2014; Platt et al., 2014; Sa´n-
chez-Rivera et al., 2014; Xue et al., 2014) and to correct disease-
causing mutations in adult stem cells (Schwank et al., 2013).
Moreover, genome-wide sgRNA libraries have been developedeports 14, 1555–1566, February 16, 2016 ª2016 The Authors 1555
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Figure 1. Conversion of hCas9 into an APC/
Cdh1 Substrate
(A) HR activity is restricted to the S phase and G2
phase of the cell cycle. Thus, hCas9-induced DNA
DSBs in the G1 phase will likely be repaired via
NHEJ, which reduces the chance for HDR to occur
in subsequent cell-cycle phases. Importantly,
the activity of the APC/Cdh1 E3 ubiquitin ligase
complex is high in the late M and G1 phases, al-
lowing proteolysis of substrates. Hence, convert-
ing hCas9 into an APC/Cdh1 substrate would limit
genome-editing activity to the S/G2/M phases and
might increase chances for HDR to occur.
(B) Schematic overview of the N-terminal region of
human Geminin. The D-Box motif mediates
recognition by the anaphase-promoting complex
and subsequent proteolysis in the G1 phase of the
cell cycle.
(C) Nucleotide sequence of the C-terminal part
of the hCas9-hGem(1/110) fusion construct. The
humanized Cas9 sequence (black) is followed by
the first 330 nt of the open reading frame of human
Geminin (red) and a stop codon (TAA).
(D) Schematic overview of expression vectors
used throughout this study. NLS, nuclear locali-
zation signal; CBh, hybrid chicken beta actin
promoter.to perform pooled loss-of-function screens (Wang et al., 2014;
Zhou et al., 2014) and to identify essential genes (Shalem et al.,
2014; Wang et al., 2015). The latter approaches, thereby, rely on
theerror-proneNHEJpathway to identifycritical genesandpoten-
tial drug targets. However, functional analysis of disease-associ-
ated sequence variants requires a precise site-specific knockin,
which is a more challenging task due to the rather low overall
activity of the HDR pathway. Importantly, the activity of the HDR
pathway is restricted to the late S and G2 phases of the cell cycle,
while the NHEJ pathway dominates DNA repair during the G1, S,
and G2 phases (Heyer et al., 2010). Thus, the error-prone NHEJ
pathway out-competes the HDR pathway, which reduces the
likelihood for precise insertions, deletions, or base substitutions1556 Cell Reports 14, 1555–1566, February 16, 2016 ª2016 The Authorsat the DSB. Chemical or genetic inter-
ruptions of the NHEJ pathway can favor
HDR, but these can be difficult to achieve
or might be harmful to cells (Shrivastav
et al., 2008; Vasquez et al., 2001). Here,
we introduce a strategy to increase the
rate of HDR by controlling the expression
and, thus, the activity of the CRISPR-
Cas9 endonuclease in a temporalmanner.
RESULTS
Recently, the Doudna lab has shown that
the controlled delivery of pre-assembled
Cas9 ribonucleoprotein (RNP) complexes
into chemically synchronized cells results
in robust HDR-mediated genome editing
(Lin et al., 2014). However, this approach
requires the optimization of cell-cyclesynchronization protocols for individual cell types and involves
multiple in vitro steps for the synthesis, purification, and assem-
bly of sgRNA-Cas9 RNP complexes.
A complementary yet unexplored strategy to control Cas9 ac-
tivity in a cell-cycle-dependent temporal manner is to convert it
into a substrate of the APC/Cdh1 complex, the major cell-cycle-
controlling E3 ubiquitin ligase. The APC/Cdh1 complex is active
in the late M and G1 phases and promotes the ubiquitination of a
variety of proteins, which leads to their degradation (Figure 1A).
One direct target of the APC/Cdh1 complex is the replication
licensing factor Geminin, which contains a destruction box motif
in its N-terminal region mediating APC recognition (Figure 1B). In
2008, Sakaue-Sawano et al. showed that the first 110 amino
acids of human Geminin are sufficient to confer nuclear localiza-
tion and cell-cycle-dependent proteolysis of fluorescent reporter
proteins, which allowed the visualization of spatiotemporal
dynamics of cell-cycle progression (Sakaue-Sawano et al.,
2008). To enable post-translational control over Cas9 in human
cells,we sought to engineer aCas9-Geminin fusion protein, here-
inafter referred to as hCas9-hGem(1/110). We envisioned that
the fusion of the first 110 amino acids of Geminin with hCas9
would result in a proteolytic destruction of hCas9-hGem(1/110)
in the late M and G1 phases, and accumulation of hCas9-
hGem(1/110) in the S/G2/M phases, which would directly couple
genome editing with HDR activities (Figure 1A). We genetically
inserted the first 330 nucleotides of the open reading frame of
human Geminin (Figure 1C) into the commonly used, bicistronic
pX330-U6-Chimeric_BB-CBh-hSpCas9 vector to generate the
pX330-U6-Chimeric_BB-CBh-hSpCas9-hGem(1/110) plasmid
(Figure 1D). This allowed a direct side-by-side comparison of
both constructs in subsequent protein expression and genome-
editing experiments.
hCas9-hGem(1/110) Protein Expression Is Cell Cycle
Dependent
First, we wanted to see whether the engineered fusion protein
is expressed at the expected size and whether we could detect
any difference in the steady-state protein levels of wild-type
hCas9 and hCas9-hGem(1/110) in human cell lines. We trans-
fected equal amounts of pX330-hSpCas9 or pX330-hSpCas9-
hGem(1/110) plasmids into HEK293T cells and, 72 hr later,
performedwestern blot and real-time qPCR expression analysis.
Both hCas9 variants were detected at their expected molecular
size (Figure 2). Notably, the hCas9-hGem(1/110) variant showed
50% reduced steady-state protein expression (Figure 2A),
which was not due to reduced mRNA expression (Figure 2B).
Cell-cycle analysis of unsynchronized HEK293T cells identified
42% of cells in the G1 phase and 58% in the S/G2/M phases
(Figure S1A), which is in good agreement with the observed
50% reduction in hCas9-hGem(1/110) protein levels, indicating
a post-translational regulation. Steady-state protein levels of
hCas9-hGem(1/110) were also lower in A549 lung cancer cells
(Figure 2C), which was, again, not caused by reduced mRNA
expression (Figure 2D). This suggests that the post-translational
regulation is not cell type restricted.
Next, we speculated that arresting cells in G2/M might
increase the protein expression of hCas9-hGem(1/110) with no
or only minor effects on wild-type hCas9. Hence, we transfected
equal amounts of the respective plasmids and synchronized
HEK293T cells with nocodazole. Indeed, hCas9-hGem(1/110)
protein levels strongly increased in synchronized cells, reaching
wild-type hCas9 levels, and mirrored endogenous Geminin
expression (Figure 2E). The same expression pattern was
observed in A549 cells (Figure S1B). This is in line with the
endogenous activity profile of the APC/Cdh1 complex, suggest-
ing that the post-translational regulation of hCas9-hGem(1/110)
is, indeed, directly controlled by the major cell-cycle-controlling
E3 ubiquitin ligase.
Finally, to rule out non-specific drug effects on protein
expression, we performed live-cell sorting. Transfected, unsyn-
chronized cells were separated according to their DNA contentCell R(Figures S1C and S1D) and followed by analysis of protein levels
from G0/G1 and S/G2/M sub-populations. Strikingly, hCas9-
hGem(1/110), but not wild-type hCas9, showed a cell-cycle-
dependent expression that mimicked the oscillating expression
pattern of endogenous Geminin (Figure 2F). Hence, hCas9
expression can be controlled in a temporal manner by an endog-
enous eukaryotic regulatory circuit.
Enhanced Homology-Directed Repair at a Single-Copy
Reporter Gene Locus by hCas9-hGem(1/110)
We hypothesized that restricting the expression and activity of
hCas9 to the S/G2/M phases of the cell cycle would result in
increased HDR-mediated repair of DSBs. To compare the two
hCas9 variants in an HDR assay, we took advantage of a cell
system similar to one recently established (Mali et al., 2013b).
Here, HEK293T cells were engineered to contain a single copy
of a disrupted EGFP gene (Figure 3A). EGFP expression can
be restored by simultaneous delivery of a promoterless EGFP
repair plasmid, an AAVS1-specific guide RNA (sgAAVS1), and
hCas9. HDR-mediated restoration of a functional EGFP gene
can be followed by flow cytometry analysis. In fact, co-delivery
of all three components resulted in a dose-dependent increase
in the number of EGFP-positive cells (Figure 3B). This dose de-
pendency might be due to altered molecular ratios between
the sgRNA:protein complexes and the repair plasmid. Impor-
tantly, hCas9-hGem(1/110) more efficiently stimulated EGFP
restoration under all conditions tested, resulting in 1.28- to
1.87-fold higher HDR rates, compared to wild-type hCas9
(Figure 3C). Of note, increasing amounts of hCas9 expression
plasmids translated into increasing amounts of hCas9 proteins,
with hCas9-hGem(1/110) showing a markedly reduced steady-
state expression under all conditions (Figure 3D). Therefore,
less hCas9 protein can increase the rate of exogenous donor-
template-mediated HDRwhen expressed at the right time during
cell-cycle progression.
hCas9-hGem(1/110) Enhanced HDR at the Endogenous
MALAT1 Non-coding RNA Locus
To compare the rates of HDR at an endogenous locus, we chose
to target the long non-coding RNA (lncRNA)MALAT1 (Gutschner
et al., 2013a). Loss-of-function analysis of lncRNAs using
traditional genome-editing technology has been challenging,
due to the lack of an open reading frame in these transcripts.
Consequently, alternative targeting strategies have been devel-
oped that rely on HDR-mediated gene disruption or replacement
(Haemmerle and Gutschner, 2015). Our previous work identified
a regionwithin theMALAT1 gene locus that is susceptible to site-
specific genome editing (Gutschner et al., 2011, 2013b). Thus,
we wanted to test whether the engineered hCas9-hGem(1/110)
could enhance HDR at this endogenous locus. We used the
CRISPR design tool (http://crispr.mit.edu/) to search for sgRNAs
targeting theMALAT1 promoter region (Figure 4A). We identified
a suitable and active sgMALAT1 thatmodified the intended locus
in a dose-dependent manner (Figure 4B). Interestingly, reduced
hCas9-hGem(1/110) protein levels under these conditions (Fig-
ure 4C) provoked similar rates of indel formation, indicating
that NHEJ pathway activity is very high throughout the cell cycle
in HEK293T cells.eports 14, 1555–1566, February 16, 2016 ª2016 The Authors 1557
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Figure 2. Cell-Cycle-Tailored Expression of hCas9-hGem(1/110)
(A–D) Representative western blots showing steady-state levels of hCas9 and hCas9-hGem(1/110) in HEK293T (A) and A549 (C) cells 72 hr after transfection with
500 ng (HEK293T) or 2 mg (A549) expression vector each. ACTB serves as loading control. (B and D) Real-time qPCR analysis of hCas9 transcript levels in
HEK293T (B) and A549 (D) cells 72 hr after transfection. Shown is the mean ± SEM of three independent experiments. IB, immunoblot; rel., relative; norm.,
normalized. *p < 0.05; **p < 0.01.
(E) Representative western blot showing expression of hCas9 variants and endogenous Geminin in HEK293T after nocodazole treatment (200 ng/ml; 22 hr).
(F) Representative western blot showing cell-cycle-resolved expression of hCas9 variants and endogenous Geminin in HEK293T. Vinculin and Ponceau S are
shown to verify equal protein loading.
All experiments were performed in biological replicates (n = 3). See also Figure S1.To assess HDR activities at theMALAT1 locus, we generated
a repair donor plasmid that contained a multiple cloning site
(MCS) flanked by homology arms (Figure 4D). Co-transfection
of this donor plasmid with sgMALAT1-containing pX330-
hSpCas9 or pX330-hSpCas9-hGem(1/110) vectors led to suc-
cessful integration of the MCS sequence, as determined by
XhoI-induced cleavage of respective PCRproducts. Importantly,
hCas9-hGem(1/110) was able to induce higher absolute rates
of exogenous donor-template-mediated HDR (Figure 4E). On
average, hCas9-hGem(1/110) increased the absolute rates of
HDR at the MALAT1 locus from 9.7% to 13.8% (hCas9 and
hCas9-hGem(1/110), respectively) (Figure 4F), with reduced
steady-state protein levels (Figure 4G). This makes hCas9-
hGem(1/110) about 1.42-fold more efficient at this particular1558 Cell Reports 14, 1555–1566, February 16, 2016 ª2016 The Authlocus and suggests that it can be a valuable gene-editing tool,
especially for genomic loci that are difficult to analyze, such as
non-coding regions of the genome.
Transient Cell Cycle Arrest in the G2/M Phases Further
Increased HDR
Finally, we wanted to investigate whether it would be possible to
further increase rates of HDR at theMALAT1 locus by transiently
arresting cells in the G2/M phases. To test this, we transfected
HEK293T cells with sgMALAT1-containing pX330-hSpCas9 or
pX330-hSpCas9-hGem(1/110) vectors, together with the MCS-
containing repair plasmid (1 mg each) and treated the cells
as depicted in Figure 5A. Indeed, we observed a significant
enhancement of targeted integration at the MALAT1 locus afterors
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Figure 3. hCas9-hGem(1/110) Enhances HDR at a Monoallelic Reporter Gene Locus
(A) Overview of the engineered single-copy EGFP locus in the HEK293T reporter cell line.
(B) Percent EGFP-positive cells analyzed 72 hr after transfection with indicated amounts of pX330 variants and repair plasmid.
(C) Relative (rel.) rates of HDR. Rate of hCas9 set to 1.
(D) Representative western blot showing expression of hCas9 variants in HEK293T 72 hr after transfection with the indicated plasmid amounts. IB, immunoblot.
All experiments were performed in biological replicates (nR 3). Data indicate the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5. Transient G2/M Cell-Cycle Arrest Further Increases HDR
(A) Timeline of cell treatments. HEK293T cells were transfected with pX330 and repair donor plasmids (1 mg each). Nocodazole (200 ng/ml) was added to
transiently arrest cells in the G2/M stahe. After 21 hr, medium was changed, and cells continued proliferation for an additional 48 hr.
(B) HDR frequency in HEK293T cells (with or without nocodazole) analyzed 100 hr after transfection of 1 mg pX330 and 1 mg MALAT1 repair donor plasmid.
(C and D) Absolute (abs.) percentage (C) and relative (rel.) rate (D) of HDR at the endogenousMALAT1 locus. Relative rate of hCas9 set to 1. All experiments were
performed in biological replicates (n = 4).
Data indicate the mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S2.a transient nocodazole-induced cell-cycle arrest (Figure 5B). The
absolute rate of HDR increased from 9.2% to 13% and from
12.7% to 16.2% for hCas9 and hCas9-hGem(1/110), respec-
tively (Figure 5C). The combined usage of hCas9-hGem(1/110)
and nocodazole was 1.74-fold more efficient than hCas9
alone (Figure 5D). This finding suggests that the combination of(B) SURVEYOR assay showing dose-dependent activity of sgMALAT1 in HEK29
(C) Representative western blot showing differential and dose-dependent expr
sgMALAT1 from pX330 vectors; 72 hr, n = 2). IB, immunoblot.
(D) Strategy for analyzing hCas9-induced HDR at the endogenous MALAT1 loc
highlighted with the HDR-Fwd (forward) primer annealing outside the left homolo
(E) HDR frequency in HEK293T cells analyzed 96 hr after transfection of 1 mg pX
(F) Absolute (abs.) rate of HDR at the MALAT1 locus. All editing experiments we
**p < 0.01.
(G) Western blot showing differential expression of hCas9 variants under genome-
pX330 vectors (1 mg each; 72 hr) in two independent experiments. Exp, experim
Cell RhCas9-hGem(1/110) with alternative methods or treatments
that enhance HDR activity or transiently prolong the S/G2/M
phases might be a valid strategy to achieve efficient site-specific
integration of exogenous DNA sequences. In line with this, we
tested the impact of SCR7, a recently described DNA Ligase
IV inhibitor (Srivastava et al., 2012). SCR7 suppresses the3T cells 72 hr after transfection of pX330 plasmids.
ession of hCas9 variants under genome-editing conditions (co-expression of
us after integration of an MCS (orange). Localization of HDR-PCR primer is
gy arm. Rev, reverse.
330 and 1 mg MALAT1 repair donor plasmid.
re performed in biological replicates (n R 3). Data indicate the mean ± SEM.
editing conditions (co-expression of repair donor plasmid and sgMALAT1 from
ent.
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NHEJ pathway and was shown to improve HDR up to 19-fold
(Chu et al., 2015; Maruyama et al., 2015). Surprisingly, we
observed only minor, non-significant increases of HDR-medi-
ated genome editing at the MALAT1 locus, using two different
SCR7 concentrations (1 mM and 10 mM) in HEK293T cells
(Figure S2). This finding, although preliminary, questions the po-
tential of SCR7 as a broadly active HDR-enhancing agent and
highlights the need for alternative small-molecule compounds
and molecular tools that have a more robust impact on HDR.
DISCUSSION
In summary, our study introduces a protein-engineering
approach to control the expression and, thus, the activity of
hCas9 in a temporalmanner,whichdiffers conceptually frompre-
viously developed inducible systems (Davis et al., 2015; Dow
et al., 2015; Polstein and Gersbach, 2015; Zetsche et al.,
2015b). We demonstrate that hCas9 can be controlled by intra-
cellular regulatory circuits. The direct coupling of its expression
with cell-cycle kinetics allows for a more efficient integration of
exogenous sequences into a specific genomic locus. Here, we
note that this regulatory conceptmight alsobeapplicable toother
genome-engineering proteins (TALEN, ZFN) and could also
enable transcriptional (Gilbert et al., 2014; Konermann et al.,
2015; Zalatan et al., 2015) or epigenetic (Hilton et al., 2015;
Kearns et al., 2015) regulation in a cell-cycle-dependent manner.
Althoughour protein-engineering strategy resulted in improved
HDR rates, we recognize that the observed enhancement in our
study is moderate compared to other recently published strate-
gies (Chu et al., 2015; Lin et al., 2014; Maruyama et al., 2015).
Moreover, our study is somewhat compounded by the rather
low overall rates of HDR. Especially, the absolute HDR rates of
0.17%–0.59% in our EGFP rescue assay (Figure 3) are about
10-fold lower than the previously reported rates using a similar
cell system (Mali et al., 2013b). One explanation might be the
use of HEK293T cells that harbor different random genomic inte-
gration sites of the disrupted EGFP gene, which might influence
EGFP restoration due to differential DNA accessibility and/or
higher order chromatin states (Wu et al., 2014). Additionally,
Mali et al. (2013b) used separate plasmids to drive the expression
of sgRNAs and hCas9, whereas the bicistronic pX330 vector de-
livers thesgRNAandhCas9 together. Thesedifferentdeliveryand
transfection strategies will ultimately lead to different molecular
stoichiometries that might influence gene-editing efficiencies.
Importantly, the observed HDR rates (about 9.7%–13.8%) at
the endogenous MALAT1 locus (Figure 4) are well within the
range of observed recombination rates after plasmid-based de-
livery of hCas9 (Mali et al., 2013b; Pinder et al., 2015). These rates
could be further increased to 12.7%–16.2% by transient G2/M
arrest (Figure 5). In contrast, Lin et al. (2014) achieved absolute
HDR rates as high as 38% upon sgRNA-Cas9 RNP complex
transfection combined with nocodazole arrest in HEK293T cells,
although these rates also varied between different gene loci and
were largely dependent on the molecular stoichiometries.
Hence, testing various amounts of the hCas9-hGem(1/110)
construct, using different guide RNAs and multiple genomic
loci in diverse cellular systems, will reveal the full potential of
this genome-engineering tool in the future.1562 Cell Reports 14, 1555–1566, February 16, 2016 ª2016 The AuthMoreover, combination of hCas9-hGem(1/110) with comple-
mentary strategies has the potential to further improve HDR.
For example, overexpression of Rad51 stimulates spontaneous
homologous recombination (HR), break-induced intrachromo-
somal HR, and gene targeting by 2- to 7-fold (Arnaudeau et al.,
1999; Lambert and Lopez, 2000; Xia et al., 1997; Ya´n˜ez and
Porter, 1999), and co-expression of Rad51 or other HR proteins
(Vasquez et al., 2001) with hCas9-hGem(1/110) might be benefi-
cial. Alternatively, the Rad51-activating small-molecule RS-1
(Jayathilaka et al., 2008) was recently shown to enhance Cas9-
based precise genome editing 3- to 6-fold (Pinder et al., 2015).
However, the RS-1 effect range was, again, largely dependent
on the molecular ratios and drug concentrations. Under opti-
mized transfection conditions, HDR was enhanced by about
1.3-fold. Interestingly, treatment of cells with L755507, a recently
discovered HDR stimulatory small molecule (Yu et al., 2015), had
no significant effect by itself but partially synergized in combina-
tion with RS-1 and increased HDR1.8-fold (Pinder et al., 2015).
It will be interesting to combine these compounds with the
cell-cycle-tailored hCas9-hGem(1/110) variant introduced in
this study.
Small-molecule-mediated inhibition of the NHEJ pathway rep-
resents a complementary approach, and DNA Ligase IV (SCR7)
as well as DNA-PK (NU7441, KU-0060648) inhibitors had been
combined with hCas9 and yielded higher HDR rates than
hCas9 alone (Chu et al., 2015; Maruyama et al., 2015; Robert
et al., 2015). SCR7 was reported to increase HDR up to 19-fold
in human cell lines at a concentration of 1 mM (Maruyama
et al., 2015). However, closer examination of the original data
indicates that the improvement can be as low as 1.8-fold (Mar-
uyama et al., 2015). Our own data (Figure S2), as well as those
of others (Pinder et al., 2015; Robert et al., 2015), indicate that
the SCR7 effect might strongly vary between different experi-
mental systems. Thus, it will be important to understand these
highly variable outcomes of the diverse molecules described
earlier to identify potent small molecules that can broadly
enhance HDR on a global rather than locus-specific or cell-
type-restricted level.
Importantly, our regulatory concept, introduced here, takes
advantage of cell-autonomous pathways to enable fluctuation
of hCas9 protein levels coupled to cell-cycle dynamics. This
resulted in higher site-specific integration events without sophis-
ticated manipulation of cells by small molecules or additional
gene-targeting reagents. Future methodological developments
may enable high-resolution expression of hCas9 and alternative
genome-engineering proteins such as Cpf1 (Zetsche et al.,
2015a) by combining cell-cycle phase-specific transcriptional
and post-translational regulatory elements. This might not only
enhance HDR efficiencies even further but may also contribute
to a better understanding of DNA repair pathways due to spatio-
temporal control of DNA damage induction.EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Treatments
HEK293T cells (CRL 3216, ATCC), the HEK293T-derivative reporter line EGIP
293T (System Biosciences), and A549 lung cancer cells (CCL 185, ATCC) were
cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mMors
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. The cells were
cultured at 37C in a humidified chamber with 5% CO2 and passaged 1:10
(A549) or 1:20 (HEK293T) twice a week. Presence of mycoplasma was
routinely tested.
24 hr prior to transfection, 100,000 cells were plated in six-well plates.
Transfection of indicated amounts of pX330 plasmids encoding respective
sgRNAs and hCas9 variants was done using Lipofectamine 2000 (Life Tech-
nologies). All transfections were performed in technical triplicates, and fresh
medium (with or without SCR7; S7742, Selleckchem) was added 7–9 hr
after transfection. Cells treated with SCR7 (1–10 mM) were grown for addi-
tional 96 hr and subjected to HDR analysis. Synchronization of cells in G2/M
was achieved by nocodazole treatment (S2775, Selleckchem; 200 ng/ml) for
20–22 hr.
CRISPR-Cas9 sgRNA Design and Plasmid Construction
The hCas9 expression plasmid (pX330) (Cong et al., 2013; Ran et al., 2013) was
acquired from Addgene (plasmid #42230). To generate the hCas9-hGem(1/
110) fusion, thepX330plasmidwasdigestedwith FseI andEcoRI. The following
DNA oligonucleotides were phosphorylated, annealed, and ligated with the di-
gested vector to introduce restriction sites for BamHI, HindIII, and XhoI:
MCS_F: CCAGGCAAAAAAGAAAAAGGGATCCAAGCTTCTCGAGG, MCS_R:
AATTCCTCGAGAAGCTTGGATCCCTTTTTCTTTTTTGCCTGGCCGG. The
N-terminal part of human Geminin (nt 208–537, NM_015895.4) encoding
amino acid residues 1–110 was synthesized by GENEWIZ and inserted into
the modified pX330 plasmid via HindIII and XhoI. Relevant sequence informa-
tion of the pX330-U6-Chimeric_BB-CBh-hSpCas9-hGem(1/110) plasmid can
be found in Figure 1C. The plasmid is available through Addgene (plasmid
#71707).
The design of sgRNAs was based on recommendations from the Zhang lab-
oratory website (http://crispr.mit.edu/). Cloning of sgRNAs into the pX330-
hCas9 plasmid or pX330-hCas9-hGem(1/110) plasmid was done as described
by Ran et al. (2013). The following DNA oligonucleotides for sgRNA cloning
were ordered from Sigma-Aldrich:
sgAAVS1_sense: 50-CACCGGGGCCACTAGGGACAGGAT-30, sgAAVS1_
antisense: 50- AAACATCCTGTCCCTAGTGGCCCC-30; sgMALAT1_sense:
50-CACCGTACGCCTCGCCCGAGCTGTG-30, sgMALAT1-antisense:50-AAA
CCACAGCTCGGGCGAGGCGTAC-30.MALAT1 Repair Donor Plasmid Construction
Left (787 bp) and right (801 bp) homology arms were amplified as described
previously (Gutschner et al., 2011) and inserted into a modified pCRII-
TOPO-TA dual promoter vector (Life Technologies). A multiple cloning site
containing BamHI, XhoI, and NotI restriction sites separates the homology
arms (see Figure 4D).
RNA Isolation and Real-Time qPCR
Cells were lyzed with TRIzol reagent (Life Technologies), and DNA-free RNA
was isolated using the Direct-zol RNA MiniPrep Kit (Zymo Research) accord-
ing to manufacturer’s recommendations. For cDNA synthesis, 1 mg total RNA
was reverse transcribed using random primers and the SuperScript III
First-Strand Synthesis system (Life Technologies). Gene expression was
measured on a Stratagene Mx3005P qPCR system (Agilent Technologies)
using SYBR GreenER qPCR SuperMix (Life Technologies). ACTB was used
as a reference gene in all real-time qPCR analyses. The following primer
pairs were used: ACTB_F: 50-TCAAGATCATTGCTCCTCCTGAG-30, ACTB_R:
50-ACATCTGCTGGAAGGTGGACA-30; Cas9_F: 50-CCGAAGAGGTCGTGAA
GAAG-30, Cas9_R: 50-GCCTTATCCAGTTCGCTCAG-30.
Immunoblot
Protein expression was analyzed as described previously (Gutschner et al.,
2014). Anti-FLAG antibody (clone M2) was purchased from Sigma-Aldrich.
Anti-Geminin antibody (#5165) was from Cell Signaling Technology. Anti-
b-Actin antibody (clone AC-74) was fromSigma-Aldrich, and anti-Vinculin anti-
body (clone V284) was from EMD Millipore. Secondary HRP (horseradish
peroxidase)-linked anti-mouse and anti-rabbit antibodies were purchasedCell Rfrom Cell Signaling Technology. ImageJ software (http://imagej.nih.gov/ij/)
was used for quantitative protein expression analysis.
Live-Cell Sorting
Prior to sorting, cells were incubated for 1 hr in medium containing Hoechst
33342 dye (5 mg/ml; Life Technologies). Cells were washed with PBS, har-
vested with Trypsin, spun down at 500 3 g for 5 min, and re-suspended in
1 ml complete medium containing Hoechst 33342 (5 mg/ml). Cells were sorted
according to their DNA content using an Influx Cell Sorter (Becton Dickinson).
Approximately 106 cells were collected per G0/G1 and S/G2/M phase.
Isolation of Genomic DNA and PCR Amplification ofMALAT1 Target
Region
Genomic DNA was isolated using the DNeasy Blood & Tissue Kit (QIAGEN).
A 393-nt region ofMALAT1, containing the target site, was amplified using the
following primer pair: MALAT1_SURV_F: 50-TTGCAGCTCAAATCTTTCCA-30,
MALAT1_SURV_R: 50- CGTTAAAAACTTAACGCTAAGCAA-30. The result-
ing PCR product was used in subsequent SURVEYOR cleavage assays
(discussed in the following text). An 1,200-bp region of MALAT1, con-
taining the target site and upstream sequences not included in the
left homology arm of the MALAT1 repair donor plasmid, was amplified
using the following primer set: MALAT1_HDR_F: 50- ACCTAACCAGG
CATAACACAGAAT-30, MALAT1_HDR_R: 50- TCTTTTCCTTCCTCATGCTAC
TCT-30. The PCR reaction was performed using 200 ng of genomic DNA and
Herculase II fusion polymerase with 53 reaction buffer (Agilent Technologies),
according to the manufacturer’s protocol. The thermocycler setting for
SURVEYOR PCR consisted of one cycle of 95C for 3 min; 31 cycles of
95C for 20 s, 57C for 30 s, and 72C for 20 s; and one cycle of 72C
for 3 min. The settings for the HDR-PCR were: one cycle of 95C for 3 min;
32 cycles of 95C for 30 s, 60C for 30 s, and 72C for 45 s; and one cycle
of 72C for 3 min. PCR products were purified using the QIAquick PCR
Purification Kit (QIAGEN).
SURVEYOR Nuclease Assay
The SURVEYOR Mutation Detection Kit for standard gel electrophoresis
(Transgenomic) was used to assess the cleavage activity of sgMALAT1. In
brief, 400 ng of SURVEYOR PCR product was incubated with Standard Taq
Reaction buffer (New England Biolabs) at 95C for 10 min in a metal heat block
to allow DNA denaturation. Heteroduplex formation was induced by slow
cooldown of the metal block after its removal from the heating block. Once
the temperature of the metal block reached 25–30C, an Enzyme-MgCl2-Mix
was added, according to the manufacturer’s protocol, and the reaction was
incubated at 42C for 45 min. SURVEYOR nuclease digestion products
(10 ml) were run on a 4%–20% gradient TBE (Tris-borate-EDTA) gel (Life Tech-
nologies). The gel was stained with SYBR Gold dye (1:10,000 diluted in fresh
TBE; Life Technologies). The gel was imaged using the ChemiDoc XRS+ Imag-
ing System with Image Lab 4.0 software (Bio-Rad) without allowing for over-
saturation of DNA bands. Cleavage intensity was estimated by measuring
the integrated intensity of the PCR amplicon and cleaved bands for each
lane using ImageJ software (http://imagej.nih.gov/ij/). The fraction of cut
PCR product was calculated using the following formula: fcut = (b + c)/(a +
b + c), where a is the integrated intensity of the undigested PCR product,
and b and c are the integrated intensities of each cleavage product.
The following equation was used to estimate indel occurrence: indel (%) =
(1  (1  fcut)1/2) 3 100.
Analysis of HDR at the Endogenous MALAT1 Locus
XhoI directly cleaves PCR products containing the newly integrated XhoI
restriction sequence as the result of successful HDR. The XhoI digestion re-
action consisted of 150 ng purified PCR product and 0.5 ml FastDigest XhoI
enzyme (Thermo Fisher Scientific) in 13 FastDigest reaction buffer. After
1 hr incubation at 37C, the reaction mixtures (10 ml) were mixed with 53
Novex Hi-Density TBE sample buffer (Life Technologies) and run on a
4%–20% gradient TBE gel (Life Technologies). Gel staining, image acquisi-
tion, and image analysis was done as described earlier (see SURVEYOR
Nuclease Assay). The percentage of HDR was calculated using the
following equation: ((b + c) / (a + b + c)) 3 100, where a is the band intensityeports 14, 1555–1566, February 16, 2016 ª2016 The Authors 1563
of the undigested full-length HDR-PCR product, and b and c are the cleav-
age products.
Analysis of HDR in the EGFP Reporter Assay
The Cas9 SmartNuclease AAVS1 Positive Control Kit (Cat. #CAS605A-1; Sys-
tem Biosciences) was purchased to analyze and compare HDR by hCas9
and hCas9-hGem(1/110) in an unbiased and reliable manner. The kit comes
with an enhanced green fluorescent inhibited protein (EGIP) reporter cell line
(HEK293T), which contains a single copy of a non-functional EGFP gene.
EGFP expression can be restored by HDR using an EGFP rescue donor
plasmid (included in the kit). This requires targeting of a 53-bp AAVS1
sequence that had been integrated into EGFP together with a stop codon
to inactivate its expression. The AAVS1 sgRNA (Mali et al., 2013b) was
cloned into the respective pX330 plasmids containing hCas9 or hCas9-
hGem(1/110). Indicated amounts of plasmids were transfected, and EGFP-
positive and viable (propidium-iodide-negative) cells were detected after
72 hr using a Gallios Flow Cytometer (Beckman Coulter). FlowJo software
v.10 was used for flow cytometry data analysis.
Statistical Analysis
Significance was assessed using two-tailed Student’s t tests after determina-
tion of the variance equality using an F test.
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